IPHA · Innate Pharma SA
$2.18
-0.36 (-14.00%)
At close · Aug 14
Market Cap
$204.71M
Shares
93.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.18
Open$2.18
Day$2.12–2.24
52W close$1.17–2.54
Avg vol 30d271K
Short int152K · 0.2% float · 27.5d
Short vol40%
Last earningsAug 14, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+26%
above
Price vs 50-day avg
+19%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
74%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
+35%
trailing
YTD return
+25%
this year
Relative strength
+21%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.16% of float · ▼ -6.8% MoM · 27.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+26%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
74%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.16% of float · ▼ -6.8% MoM · 27.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 74%
Range high $3
vs 200-day avg +26%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IPHA
this stock
Innate Pharma SA
|
$204.71M | +24.6% | — | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IPHA | +26.0% | +24.6% | +34.6% | +24.6% | +24.6% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +25.6% | +20.1% | +20.8% | +20.7% | +10.7% |